Eberhard Plattfaut

HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.

eWise Group, Inc. provides financial software solutions. It products include money manager, personal data vault, connected insights and resources. The company was founded by Alexander Grinberg in 2000 and is headquartered in Centennial, CO.

Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Cavendish Kinetics, Inc. provides radio frequency tuning solutions for mobile devices in the wireless industry. It is a fabless supplier of tunable components for RF circuits used in cellular handsets, laptops, netbooks, tablets, and other consumer wireless devices. The firm offers tunable RF circuits, based on third-generation RF MEMS technology and its semiconductor processes, let users pack more performance into the same space. The company was founded by Charles Gordon Smith and Hermann M. Hauser in 1994 and is headquartered in San Jose, CA.

MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved.

Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland.

APK AG provides recovery services of raw materials such as fossil fuels like oil, coal, gas, and renewable resources like plants. It also provides grinding and screening processes for hard rocks. The company was founded by Wolfgang Lindner in 2008 and is headquartered in Merseburg, Germany.

agnion Energy, Inc. supplies local bio-energy plants and specializes in transforming solid biomass into electricity and heat. The firm utilizes its patented Heatpipe-Reformer technology, which enables wood-based biomass to be converted into synthetic gas. Its decentralized plants can both produce synthetic natural gas (SNG) and hydrogen as well as support heat and power cogeneration. The company was founded in 2007 and is headquartered in Wilmington, DE.

GLO AB operates as a holding company. It develops technologies to fabricate defect-free, single-crystal semiconductor nanowire structures, with direct control of morphology and chemical composition. The firm focuses on the development and commercialization of light-emitting diode products using nanotechnology. Its products can be use in display, automotive and illumination application. The company was founded by Lars Ivar Samuelson, Steven Alan Morrell and Jonas Björn Ohlsson on February 25, 2003 and is headquartered in Lund, Sweden.

Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.

The German Private Equity & Venture Capital Association is the federal association of participation capital and serves as the voice of the participation capital industry. The private company is based in Berlin, Germany. The association analyzes the market and its constant development.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

Orcan Energy AG develops solutions for the optimization of energy efficiency in industrial processes and engine systems. It offers electricity generation modules based on Organic Rankine Cycle technology. The company was founded in 2008 and is headquartered in Munich, Germany.

Unternehmertum Venture Capital Partners GmbH (UVC Partners) is a venture capital subsidiary of UnternehmerTUM GmbH, founded in 2011. The firm is headquartered in Munich, Germany, with an additional office in Berlin.

coramaze technologies GmbH operates as a medical device company which develops valve repair system. It offers mitramaze a novel concept for transcatheter mitral valve repair intended for treatment of inoperable patients suffering from severe functional mitral regurgitation. The company was founded by Laura Figulla and Till Neumann in 2013 and is headquartered in Munich, Germany.

NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.

ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany.

GoodlifeMe AB engages in the development of health games. It designs SidekickHealth, which is a social health game designed to engage users through health improvement and team building. The firm provides platform and app featuring programs for diet, physical activity, and stress management. The company was founded by Saemundur Jon Oddsson and Tryggvi Thorgeirsson and is headquartered in Gothenburg, Sweden.

SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark.

Part of Freepik Co. SL, EyeEm Ltd. is a British company that provides business support services. The company is based in Birmingham, UK. EyeEm was founded in 2011.

Part of Equal 1 Laboratories Ireland Ltd., Equal1 Labs is a technology company that specializes in developing desktop quantum computers with unmatched performance, affordability, and energy efficiency. The company is based in Fremont, CA, and the CEO of the company is Dirk Leipold. The company's groundbreaking quantum processors integrate an entire quantum system onto a single chip, including millions of spin qubits, measurement and control microelectronics, AI-powered real-time error correction, and high-speed input/output.

High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany.